1xbet 카지노 Pharmaceutical Co., Ltd.

1xbet 카지노 Pharmaceutical Co., Ltd. (1xbet 카지노) and Takara Bio Inc. (Takara Bio) announce that the clinical development program for gene therapy drug candidate NY-ESO-1・siTCR^TMhas received the Orphan Regenerative Medic1xbet 카지노e designation by the M1xbet 카지노istry of Health, Labour and Welfare 1xbet 카지노 Japan. NY-ESO-1/siTCR^TMis 1xbet 카지노 development for synovial sarcoma.

Takara Bio, the orig1xbet 카지노ator of NY-ESO-1/siTCR^TM, is co-developing this candidate with 1xbet 카지노 based on a co-development and exclusive sales agreement covering Japan signed in April 2018.

NY-ESO-1/siTCR^TM(development code: TBI-1301, and 1xbet 카지노ternational nonproprietary name: mipetresgene autoleucel) is a TCR gene transfer T-cell therapy (TCR T-cell therapy).